Engineered Probiotic Delivers GLP-1 in Response to Blood Sugar Spikes

Industry Pulse News Desk · 2026-09-01

Researchers have developed a living bacterial treatment that senses elevated glucose levels and automatically secretes GLP-1 to regulate blood sugar in animal models.

Scientists have successfully engineered a strain of probiotic bacteria to monitor blood sugar levels in real time and secrete glucagon-like peptide-1, or GLP-1, in response to glucose spikes. The experimental treatment demonstrated efficacy in controlling blood sugar levels in laboratory studies using diabetic mice and non-human primates.

The living therapeutic functions by continuously sensing glucose fluctuations within the gastrointestinal tract. When blood sugar rises following food intake, the modified bacteria trigger internal production of GLP-1, a hormone that stimulates insulin release and helps manage metabolic function. Once glucose levels stabilize, the bacteria cease secretion to prevent dangerous drops in blood sugar.

Injectable GLP-1 receptor agonists have gained widespread use for the treatment of type 2 diabetes and obesity. However, standard pharmaceutical formulations require frequent injections and can cause gastrointestinal side effects due to constant hormone exposure. Researchers aim to offer a continuous, self-regulating alternative through oral administration of living biotherapeutics.

In animal models, the engineered probiotic successfully reduced blood glucose spikes without causing adverse metabolic reactions. The treatment maintained stable bacterial colonization in the digestive tract during the testing period, allowing for predictable and targeted hormone delivery following meals.

Clinical trials in humans remain necessary to evaluate the safety, dosing, and overall efficacy of the living drug. Future research will focus on ensuring long-term safety, assessing human immune system responses, and determining optimal delivery methods for potential commercial use.